These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 9511781

  • 1. Cytosine arabinoside-induced vasculitis.
    Ahmed I, Chen KR, Nakayama H, Gibson LE.
    Mayo Clin Proc; 1998 Mar; 73(3):239-42. PubMed ID: 9511781
    [Abstract] [Full Text] [Related]

  • 2. Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia.
    Bhatla D, Gerbing RB, Alonzo TA, Conner H, Ross JA, Meshinchi S, Zhai X, Zamzow T, Mehta PA, Geiger H, Perentesis J, Davies SM.
    Br J Haematol; 2009 Feb; 144(3):388-94. PubMed ID: 19036079
    [Abstract] [Full Text] [Related]

  • 3. Anterior uveitis associated with high-dose cytosine arabinoside.
    Fintelmann RE, Qian Y, Skalet A, Jeng BH.
    Ocul Immunol Inflamm; 2010 Dec; 18(6):485-7. PubMed ID: 20887203
    [Abstract] [Full Text] [Related]

  • 4. Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer.
    Esteva FJ, Soh LT, Holmes FA, Plunkett W, Meyers CA, Forman AD, Hortobagyi GN.
    Cancer Chemother Pharmacol; 2000 Dec; 46(5):382-6. PubMed ID: 11127942
    [Abstract] [Full Text] [Related]

  • 5. High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia--is more better or more of the same?
    Wolach O, Itchaki G, Bar-Natan M, Yeshurun M, Ram R, Herscovici C, Shpilberg O, Douer D, Tallman MS, Raanani P.
    Hematol Oncol; 2016 Mar; 34(1):28-35. PubMed ID: 25689584
    [Abstract] [Full Text] [Related]

  • 6. Toxic epidermal necrolysis after the use of high-dose cytosine arabinoside.
    Ozkan A, Apak H, Celkan T, Yüksel L, Yildiz I.
    Pediatr Dermatol; 2001 Mar; 18(1):38-40. PubMed ID: 11207969
    [Abstract] [Full Text] [Related]

  • 7. High-dose cytosine arabinoside-induced cutaneous reactions.
    Cetkovská P, Pizinger K, Cetkovský P.
    J Eur Acad Dermatol Venereol; 2002 Sep; 16(5):481-5. PubMed ID: 12428842
    [Abstract] [Full Text] [Related]

  • 8. Low dose cytosine arabinoside in the treatment of acute non-lymphoblastic leukemia.
    Insiripong S, Thaisamakr S.
    J Med Assoc Thai; 1996 Sep; 79(9):568-71. PubMed ID: 8996985
    [Abstract] [Full Text] [Related]

  • 9. Optimal dose and schedule of consolidation in AML: is there a standard?
    Schiffer CA.
    Best Pract Res Clin Haematol; 2014 Sep; 27(3-4):259-64. PubMed ID: 25455275
    [Abstract] [Full Text] [Related]

  • 10. Permanent cerebellar toxicity of cytosine arabinoside (Ara C) in a young woman.
    Friedman JH, Shetty N.
    Mov Disord; 2001 May; 16(3):575-7. PubMed ID: 11391764
    [Abstract] [Full Text] [Related]

  • 11. [A case of complete remission from acute myelogenous leukemia in second relapse achieved using an intermediate-dose cytosine arabinoside (ID Ara-C) regimen].
    Yoshida M, Owada N, Sasaki R, Sakamoto S, Miura Y.
    Gan To Kagaku Ryoho; 1986 Jan; 13(1):143-6. PubMed ID: 3455805
    [Abstract] [Full Text] [Related]

  • 12. High dose cytosine arabinoside is a major risk factor for the development of hepatosplenic candidiasis in patients with leukemia.
    Woolley I, Curtis D, Szer J, Fairley C, Vujovic O, Ugoni A, Spelman D.
    Leuk Lymphoma; 1997 Nov; 27(5-6):469-74. PubMed ID: 9477128
    [Abstract] [Full Text] [Related]

  • 13. Cytosine-arabinoside induced bradycardia in patient with non-Hodgkin lymphoma: a case report.
    Cil T, Kaplan MA, Altintas A, Pasa S, Isikdogan A.
    Leuk Lymphoma; 2007 Jun; 48(6):1247-9. PubMed ID: 17577797
    [No Abstract] [Full Text] [Related]

  • 14. Post-remission therapy of adult acute myeloid leukemia: high dose cytosine-arabinoside versus other consolidation regimens.
    Zeremski V, Savić A.
    Med Pregl; 2014 Jun; 67(3-4):83-90. PubMed ID: 24961049
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group.
    Avramis VI, Wiersma S, Krailo MD, Ramilo-Torno LV, Sharpe A, Liu-Mares W, Kowck R, Reaman GH, Sato JK.
    Clin Cancer Res; 1998 Jan; 4(1):45-52. PubMed ID: 9516951
    [Abstract] [Full Text] [Related]

  • 16. [High-dose cytarabine treatment in acute leukemias and leukemic meningiosis: clinical aspects and pharmacokinetics].
    Nowrousian MR, Seeber S, Miller AA, Anders C, Ohl S, Schmidt CG.
    Onkologie; 1985 Feb; 8(1):26-32. PubMed ID: 3885117
    [Abstract] [Full Text] [Related]

  • 17. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
    Hansen OP, Pedersen-Bjergaard J, Ellegaard J, Brincker H, Boesen AM, Christensen BE, Drivsholm A, Hippe E, Jans H, Jensen KB.
    Leukemia; 1991 Jun; 5(6):510-6. PubMed ID: 2056774
    [Abstract] [Full Text] [Related]

  • 18. Chemotherapy for acute non-lymphocytic leukemia with low-dose cytosine arabinoside (Ara-C).
    Lin SF, Liu HW, Chen TP.
    Nihon Ketsueki Gakkai Zasshi; 1990 Feb; 53(1):45-50. PubMed ID: 2330805
    [Abstract] [Full Text] [Related]

  • 19. Hepatotoxicity due to a possible interaction between cytosine arabinoside and dipyridamole: a case report.
    Babaoglu MO, Karadag O, Saikawa Y, Altundag K, Elkiran T, Yasar U, Bozkurt A.
    Eur J Clin Pharmacol; 2004 Aug; 60(6):455-6. PubMed ID: 15232664
    [No Abstract] [Full Text] [Related]

  • 20. [Results of therapy with high-dose cytosine arabinoside].
    Pralle H, Breithaupt H.
    Onkologie; 1985 Feb; 8(1):48, 50-2. PubMed ID: 3885122
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.